- Strengthens Adragos’ sterile manufacturing capabilities with specialized expertise in aseptic fill-finish and lyophilization.
- Marks the addition of Adragos’ 6th global manufacturing site, enhancing its ability to serve clinical and commercial pharmaceutical production needs worldwide.
Munich / Courroux – Adragos Pharma, a global pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Munich, Germany, has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. This acquisition significantly enhances Adragos’ sterile manufacturing capabilities and marks a pivotal step in the expansion of its global network.
Baccinex, based in Courroux, Jura, Switzerland, brings over 20 years of experience in sterile fill-finish processes for both liquid and lyophilized vials. Operating from its EU-GMP and US FDA-certified facility, Baccinex specializes in clinical trial supplies and small-to-medium scale commercial production, offering world-class quality and reliability to its pharmaceutical clients.
Dr. Ursula Bausch, founder and CEO of Baccinex, shared her perspective on the partnership: “Joining Adragos Pharma marks a new chapter for Baccinex. Our shared commitment to quality, innovation, and customer-centric solutions creates an exciting synergy that will enable us to deliver even greater value to our clients worldwide.”
Dr. Andreas Raabe, founder and CEO of Adragos Pharma, commented: “The acquisition of Baccinex represents a significant milestone for Adragos. Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply. This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing.”
Dr. Ursula Bausch will continue to lead Baccinex as CEO, ensuring continuity in operations and leveraging her extensive expertise in sterile manufacturing. She will also remain a shareholder in the company, reflecting her strong commitment to its continued success as part of Adragos.
The acquisition of Baccinex aligns seamlessly with Adragos’ strategy to build a world-class manufacturing network that provides tailored solutions to meet the evolving needs of its customers.
Pestalozzi Attorneys at Law acted as legal advisor to Adragos Pharma. Capitalmind Investec acted as M&A advisor, and Kellerhals Carrard acted as legal advisor to Dr. Ursula Bausch.
Terms of the transaction remain undisclosed.
